Behavioral and psychological effects of immune activation: Implications for 'depression due to a general medical condition'

Current Opinion in Psychiatry

Volumn 10, Issue 6, 1997, Pages 470-476

  Yirmiya, Raz ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE;

ANHEDONIA; ANIMAL EXPERIMENT; ANOREXIA; BRAIN; COGNITIVE DEFECT; DEPRESSION; FATIGUE; FEMALE; HUMAN; HYPERSOMNIA; IMMUNE RESPONSE; INFECTION; LIBIDO; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PSYCHOMOTOR RETARDATION; RAT; REVIEW; SYMPTOMATOLOGY; WEIGHT REDUCTION;

EID: 0030722752     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-199711000-00011     Document Type: Review

References (54)

1. Rothwell NJ, Luheshi G, Toulmond S: Cytokines and their receptors in the central nervous system: Physiology, pharmacology, and pathology. Pharmacol Ther 1996, 69:85-95.
2. Besedovsky HO, del-Rey A: Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996, 17:64-102.
3. Hart B: Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988, 12:123-137.
4. Dantzer R, Bluthe RM, Aubert A, Goodall G, Bret-Dibat JL, Kent S, Goujon E, Laye S, Parnet P, Kelley KW: Cytokine actions on behavior. In Cytokines in the nervous system. Edited by Rothwell NJ. New York: R.G. Landes Company and Chapman & Hall; 1996:117-144. A comprehensive review of the behavioral effects of cytokines, emphasising the motivational aspects of sickness behavior.
5. Watkins LR, Maier SF, Goehler LE: Cytokine-to-brain communication: a review and analysis of alternative mechanisms. Life Sci 1995, 57:1011-1026.
6. Day HEW, Akil H: Differential pattern of c-fos mRNA in rat brain following central and systemic administration of interleukin-1 beta: implications for mechanisms of action. Neuroendocrinology 1996, 63:207-218.
7. Wong ML, Bongiorno PB, Rettori V, McCann SM, Licinio J: Interleukin (IL) 1β, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc Natl Acad Sci USA 1997, 94:227-232. The expression of cytokine genes in the brain after endotoxin administration is demonstrated.
8. Swiergiel AH, Smagin GN, Dunn AJ: Influenza virus infection of mice induces anorexia: comparison with endotoxin and interleukin-1 and the effects of indomethacin. Phramacol Biochem Behav 57:389-396.
9. Kozac W, Poli V, Soszynski D, Conn CA, Leon LR, Kluger M: Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Am J Physiol 1996, 272:R621-R630. This group reports that IL-6 deficient knockout mice did not respond with fever and sickness behavior to turpentine abscess, but responded almost normally during influenza virus infection.
10. Kozak W, Soszynski D, Rudolph K, Conn CA, Kluger M: Dietary n-3 fatty acids differentially affect sickness behavior in mice during local and systemic inflammation. Am J Physiol 1997, 272:R1298-R1307.
11. Yirmiya R: Endotoxin produces a depressive-like syndrome in rats. Brain Res 1996, 711:163-174. Immune activation with endotoxin produces anhedonia and other depressive-like symptoms in rats which can be attenuated by chronic, but not acute, treatment with a tricyclic antidepressant drug.
12. Yirmiya R, Barak O, Avitsur R, Gallily R, Weidenfeld J: Intracerebral administration of Mycoplasma fermentans produces sickness behavior: role of prostaglandins. Brain Res 1997, 749:71-81.
13. Sonti G, Ilyin SE, Plata-Salaman CR: Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol 1996, 270:R1394-R1402.
14. Krueger JM, Majde JA: Microbial products and cytokines in sleep and fever regulation. Crit Rev Immunol 1994, 14:355-379.
15. Friedman EM, Reyes TM, Coe CL: Context-dependent behavioral effects of interleukin-1 in the rhesus monkey (Macaca mulata). Psychoneuroendocrinology 1996, 21:455-468.
16. Takahashi S, Kapas L, Fang J, Seyer JM, Wang Y, Krueger JM: An interleukin-1 receptor fragment inhibits spontaneous sleep and muramyl dipeptide-induced sleep in rabbits. Am J Physiol 1996, 271:R101-R108.
17. Schrott LM, Crnic LS. Anxiety behavior, exploratory behavior, and activity in NZBxNZW F1 hybrid mice: role of genotype and autoimmune disease progression. Brain Behav Immun 1996, 10:260-274.
18. Cunningham AJ, Murray CA, O'Neill LAJ, Lynch MA, O'Connor JJ: Interleukin-1β (IL-1β) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. Neurosci Lett 1996, 203:17-20.
19. Gibertini M: IL-1 beta impairs relational but not procedural rodent: learning in a water maze task. Adv Exp Med Biol 1996, 402:207-217.
20. Aubert A, Vega C, Dantzer R, Goodall G: Pyrogens specifically disrupt the acquisition of a task involving cognitive processing in the rat. Brain Behav Immun 1995, 9:129-148.
21. Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH: Progressive decline in avoidance learning paralleled by inflammatory neuro-degeneration in transgenic mice expressing interleukin-6 in the brain. Proc Natl Acad Sci USA 1997, 94:1500-1505. Transgenic mice that chronically express IL-6 from astrocytes in the brain showed a marked deficit in avoidance learning that closely corresponded with specific progressive neuropathological changes.
22. Johnson RW, Propes MJ, Shavit Y: Corticosterone modulates the behavioral and metabolic effects of lipopolysaccharide. Am J Physiol 1996, 270:R192-R198.
23. Bluthe RM, Dantzer R, Kelley KW: Central mediation of the effects of interleukin-1 on social exploration and body weight in mice. Psychoneuroendocrinology 1997, 22:1-11.
24. Watkins LR, Maier SF, Goehler LE: Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain 1995, 63:289-302.
25. Romanovsky AA, Kulchitsky VA, Akulich NV, Koulchitsky SV, Simons CT, Sessler DI, Gourine VN: First and second phases of biphasic fever: two sequential stages of the sickness syndrome. Am J Physiol 1996, 271:R244-R253.
26. Avitsur R, Pollak Y, Yirmiya R: Different receptor mechanisms mediate the effects of endotoxin and interleukin-1 on female sexual behavior. Brain Res 1997 (in press).
27. Yirmiya R, Avitsur R, Donchin O, Cohen E: Interleukin-1 inhibits sexual behavior in female but not in male rats. Brain Behav Immun 1995, 9:220-233.
28. Avitsur R, Cohen E, Yirmiya R. Effects of interleukin-1 on sexual attractivity in a model of sickness behavior. Physiol Behav 1997 (in press).
29. Sakic B, Denburg JA, Denburg SD, Szechtman H: Blunted sensitivity to sucrose in autoimmune MRL-lpr mice: a curve shift study. Brain Res Bull 1996, 41:305-311.
30. Miller NE: Some psychophysiological studies of motivation and of the behavioral effects of illness. Bull Brit Psychol Soc 1964, 17:1-20.
31. Anisman H, Kokkinidis L, Merali A: Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation. Brain Res 1996, 731:1-11. The authors demonstrated a marked decrease in bar pressing for rewarding hypothalamic electrical stimulation after IL-2 administration in rats. Evidence is provided that this effect does not involve motoric, attentional or cognitive changes, but may be attributed to specific motivational actions, possibly engendered by IL-2 induced diminution of dopamine efflux in the nucleus accumbens.
32. Bluthe RM, Michaud B, Kelley KW, Dantzer R: Vagotomy attenuates behavioral effects of interleukin-1 injected peripherally but not centrally. Neuroreport 1996, 7:1485-1488.
33. Kent S, Bret-Dibat JL, Kelley KW, Dantzer R: Mechanisms of sickness-induced decreases in food motivated behavior. Neurosci Biobehav Rev 1996, 20:171-175.
34. Shintani F, Nakaki T, Kanba S, Sato K, Yagi G, Shiozawa M, Aiso S, Kato R, Asai M: Involvement of interleukin-1 in immobilization stress-induced increase in plasma adrenocorticotropic hormone and in release of hypothalamic monoamines in the rat. J Neurosci 1995, 15:1961-1970.
35. Maier S, Watkins LR: Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res 1995, 695:279-282.
36. Smith AP, Tyrrell DAJ, Al-Nakib W, Coyle KB, Donovan CB, Higgins PG, Willman, JS. Effects of experimentally induced respiratory virus infection and illness on psychomotor performance. Neuropsychobiology 1987, 18:144-148.
37. Smith AP, Thomas M, Brockman P, Kent J, Nicholson KG: Effect of influenza B virus infection on human performance. BMJ 1993, 306:760-761.
38. Meijer A, Zakay-Rones Z, Morag A: Post-influenzal psychiatric disorder in adolescents. Acta Psychiat Scand 1988, 78:176-181.
39. Maj M: Depressive syndromes and symptoms in subjects with human immunodeficiency virus (HIV) infection. Br J Psychiatr 1996, 168:117-122. The results of the WHO Neuropsychiatric AIDS study, conducted in five geographical areas predominantly affected by the HIV epidemic, are summarized. The author suggests that the symptomatic stages of HIV infection are associated with an increased prevalence of depressive symptoms and in some contexts also with major depression.
40. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, Katlama C, Bricaire F, Duyckaerts C, Hauw JJ: Tumor necrosis factor-α, microglia and astrocytes in AIDS dementia complex. Acta Neuropathol 1997, 93:508-517. A direct correlation between the expression of TNF-α in deep white matter, astrogliosis and the degree of cognitive impairment in 12 prospectively assessed AIDS cases without focal brain lesions is demonstrated.
41. Pincus T, Griffith J, Pearce S, Isenberg D: Prevalence of self-reported depression in patients with rheumatoid arthritis. Br J Rheumatol 1996, 35:879-883.
42. Sadovnick AD, Remick RA, Allen J, Swartz E, Lee IML, Eisen K, Farquhar R, Hashimoto SA, Hooge J, Kastrukoff LF, Morrison W, Nelson J, Ogar J, Paty DW: Depression and multiple sclerosis. Neurology 1996, 46:628-632. Two-hundred and twenty-one multiple sclerosis patients were carefully evaluated using a structured clinical interview for the DSM-III-R. Patients were found to have a very high rate of depression (i.e. 50.3% lifetime risk of depression).
43. Marshal PS: Allergy and depression: a neurochemical threshold model of the relation between the illnesses. Psychol Bull 1993, 113:23-43.
44. Robinson RG: Neuropsychiatric consequences of stroke. Ann Rev Med 1996, 48:217-229.
45. Fent K, Zbinden G: Toxicity of interferon and interleukin. Trends Pharmacol Sci 1987, 8:100-105.
46. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagisni T, Nakagawa Y, Tada H et al.: Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996, 25:283-291.
47. Walker LG, Wesnes KP, Heys SD, Walker MB, Lolley J, Eremin O: The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerized assessments. Eur J Cancer 1996, 32:2275-2283.
48. Laghrissi-Thode F, Pollock BG, Szanto K, Reynolds CF: Depression and suicide in medically ill patients. Curr Opin Psychiat 1996, 9:137-140.
49. Weidenfeld J, Yirmiya R: Effect of bacterial endotoxin on the glucocorticoid feedback regulation of adrenocortical response to stress. Neuroimmunomodulation 1996, 3:352-357.
50. Maes M: Evidence for an immune response in major depression: a review and hypothesis. Prog Neuro-Psychopharmacol Biol Psychiat 1995, 19:11-38.
51. Komaroff AL, Fagioli LR, Geiger AM, Doolittle TH, Lee J, Kornish J, Gleit MA, Guerriero RT: An examination of the working case definition of chronic fatigue syndrome. Am J Med 1996, 100:56-64.
52. Cleare AJ, Beam J, Allain T, McGregor A, Wessely S, Murray RM, O'Keane V: Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Dis 1995, 34: 283-289.
53. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmuller A, Fontana A et al.: The antidepressant rollpram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med 1995, 1:244-248.
54. Xin Z, DePierre JW, Nassberger L: Tricyclic antidepressants inhibit IL-6, IL-1β and TNF-α release in human blood monocytes and IL-2 and interteron-γ in T-cells. Immunobiology 1996, 34:27-37.